Summit Therapeutics Inc. rose 15.1% on Friday, November 6, 2026, on 5,781,074 shares. The headline around the move:
Summit Therapeutics Inc. (SMMT:NASDAQ) closed at $16.33 on November 6, 2026, up 15.08% on the day. The stock trades 44.1% below its 52-week high of $29.23 and 35.3% above its 52-week low of $12.07. Over the past year, it lost 10.2%. Summit Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, SMMT closed higher on 125 days (50%). Its best day was September 3, 2026 (+17.33%) and its worst was May 1, 2026 (-24.91%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 3 times.
Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was...
Find more stocks like SMMT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.